You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,551,773


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,551,773
Title:Methods and compositions relating to improved lentiviral vectors and their applications
Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1.alpha. promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s): Trono; Didier (Vufflens-le-Chateau, CH), Salmon; Patrick (Arenthon, FR)
Assignee: Research Development Foundation (Carson City, NV)
Application Number:13/622,309
Patent Claims:1. A viral particle comprising a recombinant lentiviral vector further comprising: (a) an expression cassette comprising a transgene positioned under the control of a promoter, other than a CMV promoter, that is active to promote detectable transcription of the transgene at a signal-to-noise ratio of between about 10 and about 200 in both a human hematopoietic progenitor cell and a differentiated hematopoietic cell; and (b) an LTR region that has reduced promoter activity relative to wild-type LTR, wherein the LTR region has been rendered substantially transcriptionally inactive by virtue of deletions in the U3 region of the 3' LTR.

2. The viral particle of claim 1, further comprising an envelope protein isolated from a virus selected from the group consisting of: Moloney murine leukemia virus (MoMuLV or MMLV), Harvey murine sarcoma virus (HaMuSV or HSV), murine mammary tumor virus (MuMTV or MMTV), gibbon ape leukemia virus (GaLV or GALV), human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), and vesicular stomatitis virus (VSV) protein G (VSV G).

3. The viral particle of claim 1, wherein the recombinant lentivirus is further defined as incapable of reconstituting a wild-type lentivirus through recombination.

4. The viral particle of claim 3, wherein the recombinant lentivirus does not express a functional lentiviral gene.

5. The viral particle of claim 1, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200.

6. The viral particle of claim 1, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200.

7. The viral particle of claim 1, wherein the promoter is an EF1-.alpha. promoter, a PGK promoter, a gp91phox promoter, a MHC class II promoter, a clotting Factor IX promoter, a clotting Factor V111 promoter, an insulin promoter, a PDX1 promoter, a CD11 promoter, a CD4 promoter, a CD2 promoter or a gp47 promoter.

8. The viral particle of claim 7, wherein the transgene is positioned under the control of the EF1-.alpha. promoter.

9. The viral particle of claim 7, wherein the transgene is positioned under the control of the PGK promoter.

10. The viral particle of claim 1, wherein the transgene is a globin gene, erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb-.beta., a multidrug resistance gene, gp91phox, gp 47, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibodies (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE.

11. The viral particle of claim 10, wherein the transgene is gp91phox.

12. The viral particle of claim 10, wherein the transgene is gp 47.

13. The viral particle of claim 10, wherein the transgene is Interleukin-2.

14. The viral particle of claim 10, wherein the transgene is Interleukin-12.

15. The viral particle of claim 10, wherein the transgene is a gene coding for blood coagulation factor VIII.

16. The viral particle of claim 10, wherein the transgene is a gene coding for blood coagulation factor IX.

17. The viral particle of claim 1, further comprising a posttranscriptional regulatory sequence positioned to promote the expression of the transgene.

18. The viral particle of claim 17, wherein the posttranscriptional regulatory sequence is an intron positioned within the expression cassette.

19. The viral particle of claim 18, wherein the intron is positioned in an orientation opposite the vector genomic transcript.

20. The viral particle of claim 17, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element.

21. The viral particle of claim 20, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).

22. The viral particle of claim 21, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE).

23. The viral particle of claim 1, wherein the human hematopoietic progenitor cell is a CD34.sup.+ cell.

Details for Patent 8,551,773

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2020-11-13
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2020-11-13
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2020-11-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.